Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Roche Pharma AG | INDUSTRY |
| Merck Sharp & Dohme LLC | INDUSTRY |
| Beckett Foundation | OTHER |
| Onkologisk Forskningsfond |
Not provided
Not provided
Not provided
Not provided
This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle mass and muscle function change during oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Included patients | One-arm study. All included patients will have muscle mass and muscle function evaluated |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Evaluation of muscle mass and muscle function | Other | Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Muscle mass | We will describe if muscle mass at baseline is correlated to completion of planned systemic oncological treatment | Up to 36 months |
| Measure | Description | Time Frame |
|---|---|---|
| Muscle strength | We will describe if muscle strength at baseline is correlated to completion of planned systemic oncological treatment | Up to 36 months |
| Muscle mass changes during systemic oncological treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with localized cancer in the urinary tract undergoing neoadjuvant chemotherapy prior to radical cystektomy or patients with disseminated disease undergoing chemotherapy or immunotherapy. Patients are identified and included from Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lise Hoej Omland, MD | Contact | +45 35450782 | lise.hoej.omland@regionh.dk |
| Name | Affiliation | Role |
|---|---|---|
| Lise Hoej Omland, MD | Rigshospitalet, Denmark | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rigshospitalet | Recruiting | Copenhagen | 2100 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001749 | Urinary Bladder Neoplasms |
| D009369 | Neoplasms |
| D055948 | Sarcopenia |
| ID | Term |
|---|---|
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| UNKNOWN |
Not provided
Not provided
Not provided
We will describe if muscle mass change during systemic oncological treatment
| Up to 36 months |
| Muscle strength changes during systemic oncological treatment | We will describe if muscle mass change during systemic oncological treatment | Up to 36 months |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |